Items tagged with Research and development
Shift in discussions about R&D at this week’s World Health Assembly (post)
May 26, 2016 - Public health advocates – and many nations – had high hopes that this year’s World Health Assembly could finally agree on some alternative ways to fund research and development that can lead to affordable medical products by de-linking R&D costs from prices, through the long-awaited discussion of a landmark 2012 report of a WHO expert group on medical R&D. This week, that discussion has spread across the highest profile topics of the week such as antimicrobial resistance and emergencies, but some are concerned that the public health safeguards recommended by the expert group may be being left behind.
MSF calls on G7 leaders to urgently address the critical gaps in global response to public health emergencies and unite to lower the price of live-saving medicines (post)
Ise-Shima, Japan/Geneva May 26, 2016 - Two years since the first signs of the West Africa Ebola outbreak, the world today is little more prepared to respond to such an emergency than it was then, warns international humanitarian aid organisation Médecins Sans Frontières (MSF), while the lack of R&D into needed medicines and exorbitant medicine prices requires urgent and united action from the world leaders gathered in Japan.
WHO takes first step towards de-linking drug prices from access and innovation issues (post)
The World Health Organisation (WHO) will establish an expert technical committee that will help countries set health priorities as well as a global observatory that identifies gaps in health research and development (R&D), especially for diseases that disproportionately affect developing countries and attract little investment.
New incentives needed to develop antibiotics to fight superbugs (post)
- Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said.
Panels brainstorm ideas on innovation and drug access (post)
The quest of balance between encouraging medical innovation and the imperative of broad access to medicines has so far been elusive. Two Harvard University programmes jointly organised a workshop this week with the aim of encouraging a conversation between global health actors and see if some “outside the box” thinking is possible.
No time to wait: Lack of funding for TB drug research threatens projects (post)
Research into desperately needed new tuberculosis (TB) drugs is flagging because governments and pharmaceutical companies are not investing enough in the field, scientists warned on the eve of the 21st International AIDS conference, which begins on Monday (July 18).
How 3Ps can deliver new drugs for world's biggest killer (post)
Imagine a disease that is the world’s biggest killer, with 1.5 million people dying from it each year. It is a disease that touches every country, but some, such as South Africa, Uzbekistan and India, have been hit particularly hard. This disease has a treatment which, in its simplest form, takes six months to complete. For the complex forms, treatment causes patients to become psychotic, attempt suicide, or permanently lose their hearing due to side effects and offers a 50 percent chance of cure at best; yet in the past 50 years, only two new drugs have been developed to treat a disease that many think is extinct. The disease? Tuberculosis.
MSF general statement at the 56th Series of WIPO Assembly (post)
Médecins Sans Frontières (MSF) would like to urge WIPO and its member states to tackle the on-going challenges of spiralling drug prices and neglect of public health priorities in the IP-driven medical innovation system.
The U.S. is standing in the way of cheaper drugs for the poor (post)
Every few months, a drug company gets caught cranking up prices. Most recently, Mylan, the maker of EpiPen, took its turn in the hot seat for raising the price of a lifesaving allergy treatment by 500 percent. Congress was rightly enraged and opened yet another inquiry into pharmaceutical price gouging. Mylan offered discount coupons.
Johnson & Johnson plans to expand TB R&D in India (post)
The company along with the government of India is working to bring the most impactable drug for tuberculosis - bedaquiline to people, said Executive Vice President Paul Stoffels of Johnson & Johnson.
Page 6 of 28 · Total posts: 0
←First 5 6 7 Last→